Oxford Biomedica (LON:OXB) Stock Passes Above 200-Day Moving Average – Time to Sell?

Oxford Biomedica plc (LON:OXB)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 600.87 and traded as high as GBX 850. Oxford Biomedica shares last traded at GBX 831, with a volume of 471,700 shares traded.

Analyst Ratings Changes

Several research firms have recently commented on OXB. Canaccord Genuity Group restated a “buy” rating and issued a GBX 451 price objective on shares of Oxford Biomedica in a research note on Tuesday, October 7th. Deutsche Bank Aktiengesellschaft boosted their price target on Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a report on Friday, January 9th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Oxford Biomedica has a consensus rating of “Moderate Buy” and an average price target of GBX 606.40.

Oxford Biomedica Stock Performance

The company has a market cap of £1.00 billion, a PE ratio of -22.94 and a beta of 1.09. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. The business’s 50 day moving average is GBX 694.93 and its two-hundred day moving average is GBX 600.87.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.